Ra inks $200M discovery deal with Merck; Tris wins an FDA approval;

@FierceBiotech: Elan closes $3.25B Tysabri deal and preps for biotech deal spree. News | Follow @FierceBiotech

@JohnCFierce: AstraZeneca's latest biotech deal offers more early-stage research work. Years away from PhIII, where it needs help. More | Follow @JohnCFierce.

@RyanMFierce: Pfizer made an another early-stage deal with a Cambridge, MA biotech. This one with Gates-backed Tetragenics. Release | Follow @RyanMFierce

> Ra Pharmaceuticals has signed a deal to work with Merck ($MRK) on a new class of compounds designed to have the specificity of antibodies with the attributes of small molecules. The Cambridge, MA-based company is eligible for up to $200 million in milestones, but kept the details of the deal under wraps. "This agreement with Ra Pharmaceuticals underscores our strategy of collaborating with scientists who have developed innovative new technologies with the potential to complement and enhance our original research and product portfolio," said Richard Tillyer, who heads up discovery and preclinical work at Merck Research Laboratories. Release

> Tris Pharma says the FDA has approved Karbinal ER (carbinoxamine maleate), the first sustained-release histamine receptor blocking agent indicated for the treatment of seasonal and perennial allergic rhinitis in children ages 2 and up. Release

> The San Diego Union-Tribune profiles Regulus CEO Kleanthis Xanthopoulos. Q&A

Medical Device News

@FierceMedDev: Cardiac Science sells off diagnostic biz, focuses on defibrillators. News | Follow @FierceMedDev

@MarkHFierce: Folks have figured out a way to goose Dx tech that could enable personalized prostate cancer treatments. Release | Follow @MarkHFierce

 @DamianFierce: Now, per Reuters, Thermo Fisher is in the lead with a $12B bid on Life Tech. More | Follow @DamianFierce

> Hitachi wins FDA nod for new CT scanner. News

> U.K. regulators issue alert over Hoya's intraocular lens implant. Article

> Is Abbott trying to buy its way back into the drug biz? Item

Pharma News

@FiercePharma: Tough German pricing authority backs Pfizer/BMS drug Eliquis as stroke preventive; 'significant' benefit. Report | Follow @FiercePharma

@EricPFierce: Lilly is installing some new technology in its U.S. insulin cartridge plant, to pump up output. Article | Follow @EricPFierce

> Pfizer, Novartis eye bids for Brazil's Ache in deal worth $5B. Story

> South Africa's Adcock Ingram rebuffs buyout by conglomerate. More

> Valeant fires back at Merz with $415M-plus Obagi bid. News

Biomarkers News

 @EmilyMFierce: New prostate cancer predictors revealed. Report | Follow @EmilyMFierce

> CV biomarker study finds evidence of bias, exaggeration in the field. Story

> French researchers cast doubt on chemo biomarker's viability. Item

> Biomarkers predict risk of diabetes-related kidney trouble. Article

> U.K. team concocts rapid approach for colorectal cancer biomarker detection. More

Drug Delivery News

@MichaelGFierce: Biogen Idec's new oral MS drug Tecfidera has an unknown mechanism of action, the company says. More | Follow @MichaelGFierce

> Cholesterol 'rafts' enable cancer-killing delivery of DNA, RNA. Report

> Analysts expect nanotech drug delivery boom despite safety concerns. Story

> Pozen seeks FDA approval for layered aspirin cardiovascular treatment. Item

> FDA rejects A.P. Pharma's delayed-onset chemo drug. More

> Entrega, other startups make strides in needle-free delivery. Article

And Finally… Researchers at the University of Alabama argue that the sensation of hunger triggers a biologic response that can guard people against Alzheimer's disease. Release